89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.
复制标题
原位和转移性乳腺肿瘤中的89ZR-Radiolab曲妥珠单抗成像。
DOI：
10.3390/ph5010079
复制
发表时间：
2012-01-05
期刊：
影响因子：
--
通讯作者：
Lapi S
中科院分区：
文献类型：
--
作者：
Chang AJ;Desilva R;Jain S;Lears K;Rogers B;Lapi S
人表皮生长因子受体 2 (HER2/neu) 在 20-30% 的乳腺癌中过度表达，与肿瘤生长、血管生成和远处转移的发展相关。曲妥珠单抗是一种抗 HER2 单克隆抗体，用于治疗 HER2 阳性乳腺癌，该药物的临床疗效取决于 HER2 表达。使用放射性标记的曲妥珠单抗对 HER2 进行靶向 PET 成像可用于确定 HER2 表达水平并指导治疗选择。本研究的目的是评估一种简便的 89Zr-曲妥珠单抗制备方法，该方法可有效应用于临床级生产。此外，使用这种更简单的方法产生的 89Zr-曲妥珠单抗，通过 PET 成像评估了原位和转移性乳腺癌模型中的相对 HER2 表达水平。
The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.